Daniel Dukki Moon
Senior U.S. Associate, Washington D.C.
Education and qualifications
Duk-ki (pronounced “ducky”) represents U.S. and international clients in all phases of the U.S. merger review process and advises on a broad range of antitrust and regulatory issues related to both domestic and cross border mergers and acquisitions, joint ventures, and other business arrangements. He also counsels clients on compliance and enforcement issues related to cartels, vertical restraints, market manipulation, hub-and-spoke liability, and other antitrust law matters.
Duk-ki has particular expertise in the pharmaceuticals industry, such as advising Novartis on various transactions and antitrust matters, including its various oncology and vaccines transactions with GalxoSmithKline; and Actavis Group on its €4.25bn sale to Watson Pharmaceuticals, Inc. He is also an active member of the ABA Antitrust Section’s Health Care and Pharmaceuticals Committee, including as an associate editor for the Antitrust Health Care Chronicle and spearheading the International Antitrust Developments in Health Care and Pharmaceuticals panel series. He also has industry experience in, amongst others, oil and gas, most recently advising Western Refining, Inc. on its acquisition by Tesoro Corporation, health insurance, heavy machinery, mining, and financial institutions.
Duk-ki has advised clients on a wide range of antitrust matters, including:
- Novartis on various antitrust matters, including its series of transactions with GlaxoSmithKline
- Western Refining, Inc. on its acquisition by Tesoro Corporation before the Federal Trade Commission
- Wellpoint (now Anthem) on various antitrust matters, including its acquisition of Amerigroup
- Glencore plc on its merger with Xstrata before the DOJ
- Actavis Group on its €4.25bn sale to Watson Pharmaceuticals, Inc.
Duk-ki Moon is a Senior Associate in Linklaters’ Washington, D.C. office, starting in the New York office in 2011.
He is an active member of the ABA Antitrust Section, including as:
- Associate Editor, Health Care Chronicle, Health Care and Pharmaceuticals Committee
- Regular contributor, Recent Developments Newsletter, Health Care and Pharmaceuticals Committee
- Co-Author, “Cooperation or Compliance? In re Aftermarket Automotive Lighting and the Denial of ACPERA Protection for Unsatisfactory
- Cooperation”, Cartel & Criminal Practice Committee Newsletter, Spring 2014
- Co-head, International Antitrust Developments in Health Care and Pharmaceuticals Panel Series, Health Care and Pharmaceuticals Committee
He is a member of both the National and DC Asian Pacific American Bar Association. He is involved in diversity efforts within the firm’s Diversity Committee and the ABA Antitrust Section’s Membership & Diversity Committee.
Education and qualifications
Duk-ki obtained a Juris Doctor from the Benjamin N. Cardozo School of Law, Yeshiva University in 2011 and his undergraduate degree from the Berklee College of Music in 2007.
Duk-ki is a member of the New York State Bar, with admission pending in the District of Columbia.
- “Who's Afraid of "Killer Acquisitions?”, ABA Newsletter of the Mergers & Acquisitions Committee, Summer 2019
- "Market Definition for Innovative Pharmaceuticals: How Far Should We Go?", Antitrust Health Care Chronicle, October 2019